Galectin‐9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation

Objective evaluation of disease activity is challenging in patients with juvenile dermatomyositis (DM) due to a lack of reliable biomarkers, but it is crucial to avoid both under‐ and overtreatment of patients. Recently, we identified 2 proteins, galectin‐9 and CXCL10, whose levels are highly correlated with the extent of juvenile DM disease activity. This study was undertaken to validate galectin‐9 and CXCL10 as biomarkers for disease activity in juvenile DM, and to assess their disease specificity and potency in predicting the occurrence of flares.

[1]  L. Wedderburn,et al.  Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools , 2018, Front. Immunol..

[2]  L. L. van den Hoogen,et al.  Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome , 2018, Annals of the rheumatic diseases.

[3]  H. Krarup,et al.  Determination of anti-HCV and quantification of HCV-RNA and IP-10 from dried blood spots sent by regular mail , 2018, PloS one.

[4]  T. Niki,et al.  Role of Lgals9 Deficiency in Attenuating Nephritis and Arthritis in BALB/c Mice in a Pristane‐Induced Lupus Model , 2018, Arthritis & rheumatology.

[5]  S. Hanabuchi,et al.  Galectin-9 inhibits TLR7-mediated autoimmunity in murine lupus models , 2018, The Journal of clinical investigation.

[6]  S. Hiddingh,et al.  Effect of anticoagulants on 162 circulating immune related proteins in healthy subjects , 2017, Cytokine.

[7]  C. Huard,et al.  Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis , 2017, The British journal of dermatology.

[8]  F. Rieux-Laucat,et al.  Detection of interferon alpha protein reveals differential levels and cellular sources in disease , 2017, The Journal of experimental medicine.

[9]  P. Lachenbruch,et al.  2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative In , 2017, Arthritis & rheumatology.

[10]  N. Wulffraat,et al.  Consensus-based recommendations for the management of juvenile dermatomyositis , 2016, Annals of the rheumatic diseases.

[11]  C. Bodemer,et al.  Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease , 2016, Journal of Clinical Immunology.

[12]  T. Southwood,et al.  Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated , 2015, Arthritis & rheumatology.

[13]  S. Elahi,et al.  The bitter side of sweet: the role of Galectin‐9 in immunopathogenesis of viral infections , 2015, Reviews in medical virology.

[14]  A. Griffioen,et al.  Galectin expression in cancer diagnosis and prognosis: A systematic review. , 2015, Biochimica et biophysica acta.

[15]  P. van der Torre,et al.  Autologous stem cell transplantation leads to a change in proinflammatory plasma cytokine profile of patients with juvenile dermatomyositis correlating with disease activity , 2014, Annals of the rheumatic diseases.

[16]  J. Gottenberg,et al.  Incidence and prevalence of inflammatory myopathies: a systematic review. , 2015, Rheumatology.

[17]  F. Limongi.  The CXCR3 chemokines in inflammatory myopathies. , 2015, La Clinica terapeutica.

[18]  V. Ricotti,et al.  Increased Presence of FOXP3+ Regulatory T Cells in Inflamed Muscle of Patients with Active Juvenile Dermatomyositis Compared to Peripheral Blood , 2014, PloS one.

[19]  B. Prakken,et al.  Correlation of CXCL10, Tumor Necrosis Factor Receptor Type II, and Galectin 9 With Disease Activity in Juvenile Dermatomyositis , 2014, Arthritis & rheumatology.

[20]  I. Sjaastad,et al.  Increased Levels of Eotaxin and MCP-1 in Juvenile Dermatomyositis Median 16.8 Years after Disease Onset; Associations with Disease Activity, Duration and Organ Damage , 2014, PloS one.

[21]  E. Ferrannini,et al.  Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. , 2014, Autoimmunity reviews.

[22]  A. Kornberg,et al.  Clinical features and disease course of patients with juvenile dermatomyositis , 2013, International journal of rheumatic diseases.

[23]  M. Rice,et al.  Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis. , 2013, Arthritis and rheumatism.

[24]  S. Taback,et al.  Glucocorticoid‐related changes in body mass index among children and adolescents with rheumatic diseases , 2013, Arthritis care & research.

[25]  N. Wulffraat,et al.  The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis , 2012, Annals of the rheumatic diseases.

[26]  S. Amin,et al.  Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. , 2012, Arthritis and rheumatism.

[27]  Brian M Feldman,et al.  Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference , 2012, Arthritis care & research.

[28]  A. Martini,et al.  Glucocorticoids in paediatric rheumatology. , 2011, Clinical and experimental rheumatology.

[29]  I. Bruce,et al.  The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients , 2010, Rheumatology.

[30]  Sharon Williams,et al.  What a drop can do: Dried blood spots as a minimally invasive method for integrating biomarkers into population-based research , 2007, Demography.

[31]  T. Niewold,et al.  Lesional and nonlesional skin from patients with untreated juvenile dermatomyositis displays increased numbers of mast cells and mature plasmacytoid dendritic cells. , 2010, Arthritis and rheumatism.

[32]  B. Feldman,et al.  Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies , 2010, Arthritis care & research.

[33]  B. Feldman,et al.  Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference , 2010, Arthritis care & research.

[34]  A. Martini,et al.  Long‐term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients , 2010, Arthritis care & research.

[35]  T. Medsger,et al.  The Localized Scleroderma Skin Severity Index and Physician Global Assessment of Disease Activity: A Work in Progress Toward Development of Localized Scleroderma Outcome Measures , 2009, The Journal of Rheumatology.

[36]  S. Amin,et al.  Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. , 2009, Arthritis and rheumatism.

[37]  A. Vallejo,et al.  Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. , 2009, Arthritis and rheumatism.

[38]  W. H. Hannon,et al.  Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders. , 2009, Clinical chemistry.

[39]  B. Feldman,et al.  Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood , 2008, The Lancet.

[40]  Mitchell R Lunn,et al.  Spinal muscular atrophy , 2008, The Lancet.

[41]  Michel Fischbach,et al.  The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. , 2008, Arthritis and rheumatism.

[42]  R. Pereira,et al.  Bone mineral apparent density in juvenile dermatomyositis: the role of lean body mass and glucocorticoid use , 2008, Scandinavian journal of rheumatology.

[43]  S. Marie,et al.  International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. , 2007, Arthritis and rheumatism.

[44]  P. Lachenbruch,et al.  The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. , 2007, Rheumatology.

[45]  C. Weinberg,et al.  Seasonal birth patterns in myositis subgroups suggest an etiologic role of early environmental exposures. , 2007, Arthritis and rheumatism.

[46]  P. Gregersen,et al.  An Interferon Signature in the Peripheral Blood of Dermatomyositis Patients is Associated with Disease Activity , 2007, Molecular medicine.

[47]  L. Wedderburn,et al.  The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr. , 2006, Rheumatology.

[48]  K. Stringer,et al.  Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy. , 2005, Arthritis and rheumatism.

[49]  W. Kuis,et al.  Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. , 2005, Journal of immunological methods.

[50]  A. Dyer,et al.  History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. , 2005, Arthritis and rheumatism.

[51]  R. Hughes,et al.  119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands , 2004, Neuromuscular Disorders.

[52]  B. Feldman,et al.  Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. , 2000, Arthritis and rheumatism.

[53]  P. Lachenbruch,et al.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments , 1997 .

[54]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[55]  L. Rider.  Assessment of disease activity and its sequelae in children and adults with myositis. , 1996, Current opinion in rheumatology.

[56]  R. Petty,et al.  Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. , 1994, The Journal of rheumatology.

[57]  Brain.  Aids to the Examination of the Peripheral Nervous System , 1987 .

[58]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975, The New England journal of medicine.

[59]  A. Bohan,et al.  Polymyositis and dermatomyositis (second of two parts). , 1975 .